The essentials
EU approves Sarclisa subcutaneous form; approvals pending in US, Japan, and China.
The European Commission has approved Sarclisa in subcutaneous injectable form for multiple myeloma treatment, marking a significant expansion of the drug's therapeutic delivery options. This approval follows Sarclisa's launch across approximately 60 countries since 2020, establishing the drug as a widely distributed treatment option.
The subcutaneous formulation represents a shift from existing intravenous administration methods. Regulatory approval is pending in the United States, Japan, and China, indicating Sanofi's broader strategy to expand Sarclisa's global footprint across major pharmaceutical markets. The EU approval positions the treatment for broader European accessibility while the company pursues complementary regulatory pathways in other key regions.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Subcutaneous formulation extends Sarclisa's reach across major markets
The EU approval represents a strategic milestone in Sarclisa's global distribution network, which already spans approximately 60 countries since its 2020 launch. Pending decisions in the United States, Japan, and China signal Sanofi's focus on penetrating the world's largest pharmaceutical markets with the subcutaneous formulation, potentially reshaping treatment accessibility for myeloma patients.
Subcutaneous delivery offers alternative administration route for patients
The approved subcutaneous injectable form represents a departure from intravenous administration methods, potentially affecting patient experience and treatment feasibility. With regulatory pathways active in major markets including the US, Japan, and China, the subcutaneous option expands clinical flexibility for managing multiple myeloma across diverse healthcare settings globally.